BioCrossroads’ Post

Join Suneet Taparia, Merck, Ritu Kohli, Axtria and Rahul Maheshwari, Axtria at the Pharmaceutical Management Science Association (PMSA) 2025 Global Summit for an in-depth session on 'Accelerating GenAI Solutions through a Data Products Strategy'. Here’s what you can expect- ✔️Understand current business challenges and why a “data products strategy” is crucial to accelerating Gen AI solutions. ✔️Discover our Analytics Ready Data (ARD) products solution implemented in an accelerated timeframe. ✔️Explore two powerful Gen AI use cases and their business impact: 🔸Incentive Compensation Health Check 🔸Precision Content Personalization 👉 Register Now: https://lnkd.in/geNrreEc #PMSA2025 #GlobalSummit #Pharma #DataAnalytics #GenerativeAI

The JP Morgan Healthcare Conference 2025 highlighted major trends reshaping the biopharma industry. From strategic M&A deals to advancements in AI and regulatory changes in Asia, the event provided actionable insights for pharma and biotech companies. Get the key updates and discussions we observed that shaped this year’s event on our latest blog. 📖 Read more: https://lnkd.in/e8tvMCr8 #JPMorgan #ClinicalTrials #DrugDevelopment #CMIC

And the most productive pharma company by LoA 2006-2022 turned out to be Amgen. Jay Bradner has some serious momentum. On a side note, my estimate of my own annual capacity given sufficient funding but without increase in headcount is 9 BIC/FIC INDs per year. Now, budget constraints and the need to have 2-3 years of runway is the main constraint. IMHO, AI has significantly increased early R&D productivity and we need a set of preclinical benchmarks. https://lnkd.in/gr3Q5TvV

If you're in #London on Tuesday the 26th of November, we invite you to join us at our Zühlke Group London offices, where The Product Compound brings us together to explore the transformative role of discovery tools, with a special focus on the integration of #AI technologies. As AI and #data-driven solutions become increasingly central to the discovery and development process, a panel of industry experts will lead a discussion to look at how pharma product managers can leverage these tools to drive efficiency, speed, and examine the critical factors that influence the decision to buy versus build when it comes to discovery tools. https://lnkd.in/dfbjVPDz Tom Sharrock, PhD Dan Swerdlow Russell Sutherland, PhD Kevin Murray #pharma #pharmaceutical #productmanagement #product_management

Interesting analysis worth a read. I would have loved to break this down by therapeutic area and focus on Oncology. Thanks Alex Zhavoronkov for sharing.

🤖 AI Empowers Conduit Pharmaceuticals’ Strategy! 🌟 Conduit Pharmaceuticals leverages AI to revolutionize its drug development pipeline, driving innovation and efficiency. 🧬 This strategic integration highlights the transformative power of AI in healthcare. 🚀 Dave Tapolczay, Bill Begien, Faith Charles, JD Know complete story - https://lnkd.in/de-JcmzQ #ConduitPharma #AIInPharma #DrugDevelopment #HealthcareInnovation #FutureOfMedicine

Honored to be quoted by Fierce Biotech reporting on our analysis of the #InglationReducationAct's likely impacts on corporate #finance and #innovation. "...two new studies suggest <<<the industry's>>> fears may be overblown. Analyses of R&D spending and equity #investment in #biotech predict that the industry is capable of weathering a drop in revenue due to lower drug prices, with no corresponding loss in new approved drugs. Big Pharma “can protect both their earnings and their pipeline with pretty straightforward reallocation of R&D to late-stage development [and] continued or increased #licensing or #acquisition of early-stage products,” Fred Ledley, M.D., told Fierce Biotech in an interview. Ledley thinks the leaders already know that their companies can deal with lost revenues from lowered drug prices.  “They spent a decade implementing what they call ‘agile management’ to reallocate spending to where it's going to be most effective,” Ledley said. “They found ways to be very profitable and very productive for 20 years with all sorts of changing circumstances, and we don't think this should be a threat.” https://lnkd.in/gcuv-grX Center for Integration of Science and Industry at Bentley University, Bentley University Center for Health and Business Institute for New Economic Thinking West Health Policy Center

Sharing this great article I read this morning, written by Juergen Eckhardt of Leaps by Bayer, summarising the key trends for this year & insights from #JPM25 Key topics include: ✅An increase in dealmaking activity, including the trend toward larger deal sizes as companies seek to bolster pipelines amid a looming patent cliff for many ✅Navigating health policy questions, and the continued speculation surrounding the future of the Inflation Reduction Act (IRA) in the US ✅ A rise in Chinese Innovation, highlighting that one-third of pharma licensing deals originated from Chinese biotechs last year ✅ The dominance of AI in drug development ✅ Advancements in CGT- including recent success from Sana Biotechnology, Inc. and BlueRock Therapeutics Read more in the link in the comments below 👇 #biotech #lifesciences #JPM25

Check out this webinar on the use of digital twins in drug development: